Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
F

Current Immunotherapy and Targeted Therapy Standard of Care in Biliary Tract Cancer: Dabrafenib-Trametinib for BRAF+, Infigratinib for FGFR+, Ivsidenib for IDH-1, and Pembro for MSI-H Tumors

By Xth Eurasian Hematology-Oncology Congress FEATURING Fatih Kose
By Xth Eurasian Hematology-Oncology Congress FEATURING Fatih Kose
76 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

18:30
Pfizer Hematology

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
Gastrointestinal
17:19

New (Neo)Adjuvant Standards of Care in Gastro-Esophageal Cancer: FLO…

Xth Eurasian Hematology-Oncology Congress

M. Artac

358 views
06:28

Current Chemo Standard of Care in Biliary Tract Cancer: Cisplatin+Ge…

Xth Eurasian Hematology-Oncology Congress

F. Kose

221 views
11:12

Current Immunotherapy and Targeted Therapy Standard of Care in Bilia…

Xth Eurasian Hematology-Oncology Congress

F. Kose

76 views
17:21

Has Sorafenib Still Been the Real Winner Against New Generation TKIs…

Xth Eurasian Hematology-Oncology Congress

S. Lacin

318 views
21:17

Systemic Therapy Options for Metastatic Well-Differentiated Gastroin…

Xth Eurasian Hematology-Oncology Congress

A. Kouzminov

173 views
18:59

Is Tumor Sidedness, Biomarkers or Molecular Subtype Classification M…

Xth Eurasian Hematology-Oncology Congress

G. Demir

19 views